MLAB · Mesa Laboratories Inc · Analyst Estimates
$131.32
+2.07 (+1.60%)
At close · Oct 28
View the 10-K filed Jun 3, 2026
Return incl. dividend (before tax)
Q1 2027 earnings call transcript
Customer concentration
— top customer 20% of revenue
One customer — 20% of revenue (fiscal 2026)
“In our Clinical Genomics division, a significant portion of revenues is generated from ongoing purchases by a relatively small number of established customers, with a single customer accounting for approximately 20% of the division's revenues in fiscal 2026.”
Market Cap
$723.27M
Shares
5.60M
Volume · Oct 28
143.45K
Avg daily vol (3M)
129.91K
Analyst Estimates
Compare analyst forecasts for Mesa Laboratories Inc across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-10-01 01:37 UTC · Publication dates shown per estimate · 8 metric / period groups
FY ending 2027-03-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
9.95
|
9.95
|
9.95
|
1
|
11.62
|
11.62
|
11.62
|
5.39
|
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
251.70M
|
254.45M
|
257.20M
|
2
|
— | — | — | — | — | — | — | — |
FY ending 2028-03-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
10.27
|
10.27
|
10.27
|
1
|
12.27
|
12.27
|
12.27
|
0.00
|
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
265.20M
|
270.85M
|
276.50M
|
2
|
— | — | — | — | — | — | — | — |
Q ending 2026-09-30
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
2.24
|
2.24
|
2.24
|
1
|
2.73
|
2.73
|
2.73
|
1.26
|
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
60.60M
|
62.20M
|
63.80M
|
2
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
2.71
|
2.71
|
2.71
|
1
|
3.33
|
3.33
|
3.33
|
1.67
|
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
65.50M
|
65.95M
|
66.40M
|
2
|
— | — | — | — | — | — | — | — |
Key facts
CIK
724004
CUSIP
59064R109
13F (30d)
25 filings
25 filers
Visit website
Investor relations